VNRX News & Events

VolitionRx announced the appointment of two new centralized laboratory providers of its Nu.Q Vet Cancer test in the U.S. and Asia, further expanding access to its canine cancer early detection tool. Midwest Veterinary Laboratory, a full-service independent reference laboratory in the U.S., will be offering the Nu.Q Vet Cancer test to its customers across all 50 states from February 2026. Bioguard, a global animal health diagnostics company is now offering the Nu.Q Vet Cancer Test through its Animal Health Diagnostic Center, the first certified ISO/IEC 17025 animal disease testing laboratory in Taiwan and China.

VolitionRx announces results from a clinical study demonstrating the high accuracy of its Nu.Q Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species. At 100% specificity, i.e. no false positives, the assay detected over 80% of feline lymphomas. This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine.

VolitionRx announces preprint availability of a new manuscript entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy." This paper showcases both a new method, Capture-Seq, and new biomarkers for the detection of cancer. Volition has achieved 180-fold enrichment through its focus on chromosome fragments. Dr Jake Micallef, Chief Scientific Officer, Volition commented: "This is, I believe, a world-first breakthrough - it is the first time that transcription factor-bound DNA has been physically separated from the massive amounts of background DNA in the blood, and could, in my opinion, represent the biggest scientific breakthrough in cancer testing in recent years."